IngredientsDarlingtonia californica is a species of carnivorous plant in the New World pitcher plant family, Sarraceniaceae. The cobra lily is the sole species within its monotypic genus, Darlingtonia. Its accepted scientific name is Darlingtonia californica Torr., with a historical synonym of Chrysamphora californica. The plant is also called the California pitcher plant or Oregon pitcher plant, as well as the Cascadian pitcher plant by extension. It is commonly called the cobra lily or cobra plant; the name "cobra lily" stems from the resemblance of its tubular leaves to a rearing cobra, complete with a forked leaf — ranging from yellow to purplish-green — that resembles fangs or a serpent's tongue.
Darlingtonia californica is a carnivorous plant that lures, traps, and dissolves insects with its pitcher-shaped leaves. Insects are lured to the slippery pitchers by color and nectar. Once the insect enters the bulbous top of the pitcher, it becomes disoriented by the translucent quality of the leaves. The insect has difficulty determining which way to exit. Eventually, the insect gets trapped inside the tube and slides downward toward the bottom of the pitcher, where it is dissolved and absorbed as nutrients by the plant.
The long, tubular green leaves have prominent purple-red veins. They arch at the top so that the opening faces downward like a hood. Hanging from these hooded tubes are forked leaves that look like serpents' tongues. The upright hooded tubes, together with the "tongues," resemble cobras ready to strike. The California pitcher plant can grow up to 3 feet tall and turns shades of red and brown with age. The light green and red flowers point downward, possibly to keep rain away from the pollen.
The Darlingtonia californica has an ingenious tiny, hidden exit and multiple translucent false exits, making it even better at capturing and retaining its prey. The cells inside the tube can absorb nutrients like roots do, which helps supplement the plant's nitrogen requirements. Plants create large mats by slowly spreading rhizomes. Vegetative reproduction is more common than reproduction by seed.
The plant was discovered during the Wilkes Expedition of 1841 by botanist William D. Brackenridge at Mount Shasta, Northern California. In 1853, it was described by John Torrey, who named the genus Darlingtonia after Philadelphian botanist William Darlington (1782–1863).
The cobra lily is native to Northern California and Oregon, in the western United States. The cobra lily has evolved into life along the West Coast and in the lower Pacific Northwest through its carnivorous adaptations, where it may be found near bogs, vernal pools, on forested rocky slopes (near snowmelt, especially), creeks, or near seeps with cold running water, usually on serpentine soils. It ranges from Oregon to northern California and thrives in redwood and red fir forests up to 2,000 metres (6,000 feet) above sea level, where temperatures remain below about 18 °C (65 °F).
The cobra plant is not just restricted to nutrient-poor acidic bogs and seepage slopes; many colonies actually thrive in ultramafic soils, which are in fact basic soils, within its range. In common with most carnivorous plants, the cobra lily is adapted to supplementing its nitrogen requirements through carnivory, which helps to compensate for the lack of available nitrogen in such habitats.
The cobra lily has a very large and rambling root system compared to those of other carnivorous plants in the family Sarraceniaceae. The cobra lily is able to survive fire by regenerating from its roots, but despite this important role, the roots are very delicate organs.
Despite a lack of definitive clinical evidence, the California Pitcher Plant continues to be valued for its unique phytochemical profile and historical significance. Its inclusion in nutritional products underscores the growing interest in botanical diversity and traditional remedies. When encountered in the commercial supplement space, it is typically encountered in dried leaf/pitcher preparations, liquid extracts, or tinctures, generally mirroring the preparation forms used for its close relative Sarracenia purpurea in the same plant family. No standardized pharmaceutical or pharmacopeial preparations have been formally developed exclusively for D. californica.
It is important to distinguish carefully between traditional uses documented for Darlingtonia californica specifically and those documented for its close relatives in the Sarraceniaceae family, particularly Sarracenia purpurea (purple pitcher plant), which has a substantially more extensive and better-documented ethnobotanical record. The Sarraceniaceae family is relatively poorly described in terms of chemical constituents, which is surprising given the fact that Sarracenia species have long been used as traditional medicine by many aboriginal communities in North America. However, Darlingtonia californica has not been chemically investigated at all to date relative to its Sarraceniaceae relatives.
The name Darlingtonia californica Torr. appears in documented lists of medicinal plants used during and around the California Mission period. However, specific documented preparation methods, tribal affiliations, or conditions for which D. californica itself — as distinct from the more eastern pitcher plants — was used are not established in the available peer-reviewed ethnobotanical literature. The plant's restricted geographic range, confined to northern California and Oregon rather than southern California where most California missions were located, further limits what can be reliably documented about its traditional use in indigenous Californian medicine.
Because D. californica belongs to the same family as Sarracenia purpurea and occupies related ecological roles, its traditional and supplement use is often discussed in parallel. The pitcher plant has a long history of use as a traditional medicine among indigenous peoples across the continent, and has been used for a wide variety of conditions including gynecological aid, liver and kidney complaints, and is even reported as a treatment of smallpox during the 19th century. The leaves of this plant have been reportedly used in the treatment of dyspepsia and constipation. Leaves of S. purpurea are used medicinally by the Cree First Nation of Eeyou Istchee, James Bay region, Quebec, Canada.
By the end of the 19th century, several surgeons and practitioners related to the US Army, as well as the botanist Charles F. Millspaugh (1892), described the use of poultices and infusions from the Indigenous medical flora based on the plant Sarracenia purpurea (family Sarraceniaceae) to be effective for treating smallpox, in a likely case of medical appropriation of Indigenous therapeutic knowledge. The attention of the medical world was first called to Sarracenia purpurea by Drs. Herbert Miles and F. W. Morris, both of Halifax, N. S., in 1861 and 1862, both recommending its use in the treatment of smallpox.
Sarraceniaceae plants have been of horticultural interest for well over one hundred years, which has often put them at risk of being poached. Their significance also stems from being used for centuries to prepare medicine, particularly by people indigenous to the area they occupy.
As of the most recent published research, Darlingtonia californica has not been chemically investigated independently to the depth of its Sarraceniaceae relatives; however, several insect-attracting constituents have been described from related genera. Various compounds found in Sarracenia have been reported, including volatiles, flavonoids, phytochemicals, and pitcher fluid composition.
The most specific and authoritative published phytochemical characterization of D. californica to date comes from a 2017 paper in PLOS ONE by Hotti et al. (VTT Technical Research Centre of Finland and the Institute for Molecular Medicine Finland, University of Helsinki). Sarraceniaceae is a New World carnivorous plant family comprising three genera: Darlingtonia, Heliamphora, and Sarracenia. The plants occur in nutrient-poor environments and have developed insectivorous capability in order to supplement their nutrient uptake. The aim of the research was to investigate the occurrence of coniine in Sarracenia and Darlingtonia and to identify common constituents of both genera, unique compounds for individual variants, and floral scent chemicals. In this comprehensive metabolic profiling study, the authors looked for compound patterns associated with the taxonomy of Sarracenia species. In total, 57 different Sarracenia and D. californica accessions were used for metabolite content screening by gas chromatography-mass spectrometry. The resulting high-dimensional data were studied using a data mining approach. The two genera are characterized by a large number of metabolites and huge chemical diversity between different species.
Studied accessions of Sarraceniaceae possessed a diverse variety of compounds. Lids and pitchers were studied separately, and approximately 600 compounds were detected in both collections. The accessions also showed huge diversity, with every accession containing unique compounds.
Among the common constituents of Sarraceniaceae are sarracenin, erucamide, and nonanal. Sarracenin, an enol diacetal monoterpene, was first identified in S. flava and later found in a number of Sarracenia and Heliamphora species.
Although transcriptome analysis did not reveal a candidate gene for coniine biosynthesis, the use of a sensitive selected ion monitoring method enabled the detection of coniine in eight Sarracenia species, showing that it is more widespread in this genus than previously believed. Sarracenia flava contains the alkaloid coniine, otherwise only found in Conium maculatum (hemlock), in which its biosynthesis has been studied, and several Aloe species. Its ecological role and biosynthetic origin in S. flava is speculative.
Darlingtonia, Heliamphora, and Sarracenia plants are rich in compounds with potential pharmaceutical and medical uses. These belong to several classes such as flavonoids, with flavonol glycosides being the most abundant, monoterpenes, triterpenes, sesquiterpenes, fatty acids, alkaloids, and others. Some of them are well characterized in terms of chemical properties and biological activity and have widespread commercial applications.
Carnivorous plants have fascinated researchers for centuries because of their mode of nutrition which is unlike that of other plants. They are able to produce bioactive compounds used to attract, capture, and digest prey, but also as a defense mechanism against microorganisms and free radicals.
Of the broad compound classes identified across Sarraceniaceae — and where D. californica was included in profiling studies — the following deserve particular note:
Scientific validation of the California Pitcher Plant's health benefits remains limited. While in vitro studies on other carnivorous plants suggest potential therapeutic effects, such as anti-inflammatory or antimicrobial properties, there are currently no published clinical trials specifically evaluating Darlingtonia californica in human health applications. Most evidence remains anecdotal or extrapolated from closely related species.
The most developed area of research relevant to Sarraceniaceae as a broader category is antioxidant and cytoprotective activity. Sarracenia species have attracted renewed pharmaceutical interest due to recent investigations revealing their cytoprotective activities in cell models. The root extract of S. purpurea, obtained by 100% acetone, had the highest anticancer activities, antioxidation capacity (DPPH activity with IC50 of 89.3 ± 2.2 μg/mL), antibacterial activities, total phenolic content (33.4 ± 0.7 mg GAE/g), and total flavonoid content (107.9 ± 2.2 mg QUE/g). These results apply specifically to Sarracenia purpurea, not to D. californica; they are noted here for comparative context within the plant family.
Compounds identified from Sarraceniaceae plants have anti-inflammatory, anticancer, antimicrobial, antiviral, cardioprotective, hepatoprotective, or neuroprotective abilities proven both in vitro and in vivo. The main purpose of the 2022 review (published in International Journal of Molecular Sciences) was to provide an overview of the secondary metabolites with significant biological activity found in the Sarraceniaceae family. The review also underlines the necessity of future studies for the biochemical characterization of the less-investigated species. As D. californica is explicitly among the "less investigated species," these findings cannot be directly applied to it without further dedicated research.
Within Sarraceniaceae secondary metabolites, morroniside (an iridoid glycoside found in related species) downregulates factors associated with inflammation and cartilage degradation in chondrocytes, suggesting a potential protective bioactive role against osteoarthritis. In neurodegenerative disease models, morroniside inhibits the phosphorylation of JNK, p38/MAPK and tau, and is thought to potentially aid in the treatment of Alzheimer's disease. These are in vitro and animal-model findings for compounds in the broader Sarraceniaceae family, not specific clinical findings for D. californica.
Taxifolin (dihydroquercetin), a flavanonol with two stereocenters, has glycosides found in medicinal plants. In in vitro and in vivo studies, taxifolin displays a wide range of health-promoting effects and biological activities such as antioxidant, anti-inflammatory, anti-Alzheimer, anticancer, and antiangiogenic. The structural orientation of taxifolin makes this compound capable of scavenging free radicals, which corresponds to its antioxidant efficacy. However, these findings are for taxifolin as a compound in general, not specifically as extracted from D. californica.
The carnivorous pitcher plant Sarracenia purpurea exhibits many ethnobotanical uses including the treatment of type 2 diabetes and tuberculosis-like symptoms. Studies have prepared different extracts from leaves (pitchers), stems, and roots of S. purpurea and investigated their antioxidant and anticancer properties. Compounds with chemopreventive and therapeutic potential belonging to three main groups (naphthoquinones, flavonoids, phenolic acids) have already been isolated from carnivorous plants of several genera, mainly Dionaea, Drosera, and Nepenthes. These substances are recognized as having potential for prevention and treatment of various diseases such as diabetes, cancer, neurodegenerative disease, cardiovascular disease, and atherosclerosis. None of this work has been replicated specifically for D. californica in human or clinical settings.
The purple pitcher plant Sarracenia purpurea is a medicinal plant used by the Canadian First Nations to treat a wide variety of illnesses. The Mi'kmaq and Wolastoqiyik (Maliseet) peoples of Eastern Canada have traditionally used infusions of S. purpurea for the treatment of tuberculosis-like symptoms. Previous investigations have shown methanolic extracts of S. purpurea to possess antimycobacterial activity. Again, this body of work is specific to S. purpurea, not D. californica.
The leaf extract of S. purpurea exhibits several ethnobotanical uses in many aboriginal communities. For example, the leaf extract of S. purpurea is a traditional medicine for the treatment of type 2 diabetes. These findings apply to S. purpurea specifically and have not been replicated for D. californica.
In aggregate, there are no published human or clinical trials specifically examining Darlingtonia californica as a dietary supplement or therapeutic agent. There are currently no published clinical trials specifically evaluating Darlingtonia californica in human health applications. This review underscores that Sarraceniaceae species contain numerous substances with the potential to advance health. Future perspectives should focus on the discovery of new molecules and increasing the production of known compounds using biotechnological methods. The available evidence is limited to: (a) phytochemical characterization studies identifying compound classes present in the genus and family; (b) in vitro and in vivo animal data for specific compounds identified in related species; and (c) ethnobotanical documentation, primarily for Sarracenia purpurea.
Based on the available phytochemical and pharmacological literature for Sarraceniaceae as a family — and with the explicit caveat that none of this evidence is specific to clinical use of D. californica — the following body system associations have been described in the scientific literature for the secondary metabolites identified across the family:
There are currently no published clinical trials specifically evaluating Darlingtonia californica in human health applications. As a direct consequence of this research gap, there are no scientifically established or clinically validated dosages for Darlingtonia californica as a dietary supplement. No official pharmacopeial monograph (USP, European Pharmacopoeia, WHO, German Commission E, or ESCOP) exists for this species.
In the peer-reviewed phytochemical literature, plant material was processed and analyzed as dried and extracted samples without reference to human therapeutic dosing. In total, 57 different Sarracenia and D. californica accessions were used for metabolite content screening by gas chromatography-mass spectrometry in the key 2017 metabolite profiling study — a purely analytical context, not a clinical dosing context.
The comparator species Sarracenia purpurea has been used in laboratory extraction studies using solvents including methanol, ethanol, acetone, and distilled water, but these preparation parameters also do not translate to validated human doses. More rigorous studies are needed to fully substantiate the safety and efficacy of California Pitcher Plant in human nutrition and health.
Darlingtonia californica is globally assessed as Least Concern by the IUCN (assessed 2000), owing to its stable populations within its endemic range spanning southwestern Oregon and northern California, despite a relatively restricted overall distribution. Locally, however, the species is considered vulnerable in California, where the California Native Plant Society (CNPS) ranks it as 4.2 — indicating a plant of limited distribution that is fairly threatened — primarily due to its narrow habitat preferences and small range size.
Darlingtonia californica is ranked 4.2, Plants of Limited Distribution, A Watch List; Moderately threatened in California. Alteration to natural hydrological regimes is recognized as a threat to Darlingtonia californica in the northwestern United States. It is currently threatened by habitat disruption and unscrupulous collectors.
California pitcherplant is listed as threatened in the Family Lists of Candidate Endangered and Threatened Plant Species in the Continental United States (Smithsonian Institution 1975). These conservation designations have direct implications for the sourcing of plant material: wild collection of D. californica is ethically problematic and in some jurisdictions legally restricted, given its limited range and vulnerability to habitat disruption and collection pressure.
A notable safety consideration for the Sarraceniaceae family as a whole is the confirmed presence of coniine in multiple Sarracenia species. Coniine is otherwise only found in Conium maculatum (poison hemlock), in which its biosynthesis has been studied, and several Aloe species. A sensitive selected ion monitoring method enabled the detection of coniine in eight Sarracenia species, showing that it is more widespread in this genus than previously believed. Whether coniine occurs in D. californica specifically was part of the investigative scope of the 2017 study; the compound screening of D. californica accessions was included, and both shared and specific constituents were identified. The implications of any coniine presence for human safety in supplement preparations have not been formally assessed for D. californica.
There are currently no published clinical trials specifically evaluating Darlingtonia californica in human health applications. Most evidence remains anecdotal or extrapolated from closely related species. The formal toxicological profile of D. californica — including acute and chronic toxicity, genotoxicity, reproductive toxicity, and drug interactions — has not been established in any peer-reviewed publication identified in the literature. No regulatory agency (FDA, EMA, Health Canada) has issued a safety opinion or authorized any health claim specifically for D. californica preparations.
The North Carolina State Extension Gardener Plant Toolbox notes it as non-toxic for cats, horses, and dogs in the context of an ornamental plant database, but this classification does not constitute a human safety profile and cannot be extrapolated to therapeutic supplement use.
The California Pitcher Plant is very attractive in the wild and eagerly sought for cultivation; however, it is difficult to grow outside its cool native range and has exacting requirements for temperature and humidity and wet, bog-like conditions. These cultivation challenges, combined with its conservation watch-list status, mean that any commercially available material sourced from wild populations raises significant ecological and legal concerns. Many wild carnivorous plants have gone extinct since the arrivals of Europeans. It is estimated that only five percent of the wild carnivorous plants remain. Supplement products containing D. californica should therefore be evaluated carefully for their sourcing transparency.
Health conditions that California pitcher plant may help support.
Body systems that California pitcher plant may help support.
Go back